Patents by Inventor Nemichand B. Jain
Nemichand B. Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938224Abstract: A 12-hour anti-tussive modified release solid tablet or tablet-in-capsule is described which comprises a benzonatate-silicon dioxide adsorbate powder in a hydrophilic matrix to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 1% release of the benzonatate within half an hour as determined in an in vitro dissolution assay.Type: GrantFiled: August 19, 2021Date of Patent: March 26, 2024Assignee: TRIS PHARMA INCInventors: Andrea Nelson, Sachin Chaudhari, Nemichand B. Jain, Shivanand Puthli
-
Publication number: 20230069979Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.Type: ApplicationFiled: November 17, 2022Publication date: March 9, 2023Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
-
Publication number: 20220211668Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.Type: ApplicationFiled: March 24, 2022Publication date: July 7, 2022Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
-
Patent number: 11160786Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.Type: GrantFiled: April 4, 2017Date of Patent: November 2, 2021Assignee: APRECIA PHARMACEUTICALS LLCInventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
-
Publication number: 20170258763Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.Type: ApplicationFiled: May 16, 2017Publication date: September 14, 2017Applicant: APRECIA PHARMACEUTICALS COMPANYInventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
-
Publication number: 20170202807Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.Type: ApplicationFiled: April 4, 2017Publication date: July 20, 2017Applicant: APRECIA PHARMACEUTICALS COMPANYInventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
-
Patent number: 9669009Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.Type: GrantFiled: April 11, 2016Date of Patent: June 6, 2017Assignee: Aprecia Pharmaceuticals CompanyInventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
-
Publication number: 20160220534Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Applicant: APRECIA PHARMACEUTICALS COMPANYInventors: Jules JACOB, Norman COYLE, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT, Nemichand B. JAIN
-
Patent number: 9339489Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.Type: GrantFiled: May 15, 2014Date of Patent: May 17, 2016Assignee: Aprecia Pharmaceuticals CompanyInventors: Jules Jacob, Norman Coyle, Thomas G West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
-
Publication number: 20140271862Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.Type: ApplicationFiled: May 15, 2014Publication date: September 18, 2014Applicant: APRECIA PHARMACEUTICALS COMPANYInventors: Jules JACOB, Norman COYLE, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT, Nemichand B. JAIN
-
Patent number: 7135465Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.Type: GrantFiled: March 29, 2001Date of Patent: November 14, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
-
Publication number: 20040005358Abstract: A modified-release vasopeptidase inhibitor formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE inhibitory activity, in a balanced manner, for a predetermined duration to lower blood pressure and/or treat heart failure. In a preferred formulation, the NEP inhibitory activity and ACE inhibitory activity have balanced release characteristics.Type: ApplicationFiled: April 21, 2003Publication date: January 8, 2004Inventors: Peter H. Slugg, Nemichand B. Jain, Rajesh Krishna, Robert L. Jerzewski, Ronald L. Smith, Jatin M. Patel, Bimal K. Malhotra
-
Publication number: 20020034546Abstract: A pharmaceutical composition is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a statin, such as pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin, in combination with aspirin, in a manner to minimize interaction of aspirin with the statin and minimize side effects of aspirin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.Type: ApplicationFiled: April 2, 2001Publication date: March 21, 2002Inventors: Ismat Ullah, Nemichand B. Jain
-
Publication number: 20020002147Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.Type: ApplicationFiled: March 29, 2001Publication date: January 3, 2002Inventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
-
Patent number: 6235311Abstract: A pharmaceutical composition is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a statin, such as pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin, in combination with aspirin, in a manner to minimize interaction of aspirin with the statin and minimize side effects of aspirin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.Type: GrantFiled: March 18, 1998Date of Patent: May 22, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Nemichand B. Jain
-
Patent number: 5536507Abstract: A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large intestine. The first component comprises the pharmacologically active substance, microcrystalline cellulose, a pH-sensitive polymer, and optionally an osmotic agent. The second component is a delayed release coating, and the third component is an enteric coating.Type: GrantFiled: June 24, 1994Date of Patent: July 16, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Robert Abramowitz, Sunanda A. Ranadive, Sailesh A. Varia, Nemichand B. Jain
-
Patent number: 5506248Abstract: An ifetroban composition is provided which has good dissolution properties even on aging, when dispersed in water has a pH of at least 7 and includes a salt of ifetroban, one or more basifying agents, such as magnesium oxide or calcium carbonate, and where in tablet form includes one or more fillers such as mannitol and/or microcrystalline cellulose, one or more disintegrating agents such as crospovidone, one or more lubricants such as magnesium stearate, optionally one or more glidants such as colloidal silicon dioxide, one or more binders such as pregelatinized starch (dry binder) or polyvinyl-pyrrolidone (wet binder) and optionally a film coating containing a film former such as hydroxypropyl cellulose and a plasticizer such as 1,2,3-propanetriol triacetate.Type: GrantFiled: May 22, 1995Date of Patent: April 9, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Faranak Nikfar, Abu T. M. Serajuddin, Robert L. Jerzewski, Nemichand B. Jain
-
Patent number: 5180589Abstract: A pharmaceutical composition is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.Type: GrantFiled: May 20, 1991Date of Patent: January 19, 1993Assignee: E. R. Squibb & Sons, Inc.Inventors: Yatindra M. Joshi, Pierina Chiesa, Nemichand B. Jain
-
Patent number: 5158777Abstract: A formulation comprising captopril within an enteric or delayed release coated pH stable core combined with additional captopril that is available for immediate release following administration.Type: GrantFiled: August 16, 1991Date of Patent: October 27, 1992Assignee: E. R. Squibb & Sons, Inc.Inventors: Robert Abramowitz, Yatinda M. Joshi, Nemichand B. Jain
-
Patent number: 5030447Abstract: A pharmaceutical compositions is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as mirocrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.Type: GrantFiled: March 31, 1988Date of Patent: July 9, 1991Assignee: E. R. Squibb & Sons, Inc.Inventors: Yatindra M. Joshi, Pierina Chiesa, Nemichand B. Jain